Other languages Lipella Pharmaceuticals Inc.

Equities

LIPO

US53630L1008

Market Closed - Nasdaq Other stock markets 02:00:01 21/05/2024 am IST			5-day change	1st Jan Change
0.755 ^USD	+0.53%		+3.04%	-25.98%

09/05	Lipella Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
17/04	Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lipella Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board	17/04
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline	05/03
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Wall Street Set to Open Lower Friday; Employment Growth Tops Forecasts	08/12
Top Premarket Decliners	08/12
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Sector Update: Health Care Stocks Softer Late Afternoon	21/23/21
Top Midday Gainers	20/23/20
Sector Update: Health Care Stocks Slightly Higher Friday Afternoon	20/23/20
Sector Update: Health Care	20/23/20
Lipella Pharmaceuticals Says US FDA Approves IND Status for LP-310 for Oral Lichen Planus; Shares Surge	20/23/20
Investors Remain Cautious Over Fed Moves, Setting Wall Street Up for Lower Open	20/23/20
Lipella Pharmaceuticals Inc. Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus	20/23/20
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15
Lipella Pharmaceuticals Inc. Appoints Lori Birder as a Member of the Board	24/23/24
Lipella Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	13/23/13
Lipella Pharmaceuticals Enters Manufacturing Deal With Cook MyoSite for Potential Treatment of Hemorrhagic Cystitis	17/23/17
Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite	17/23/17
Lipella Pharmaceuticals Doses First Patient in Bladder MRI Contrast Agent Trial	05/23/05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Lipella Pharmaceuticals Inc.

Equities

LIPO

US53630L1008

Other languages

Filters